Get the latest news, insights, and market updates on ARVN (Arvinas, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
How the Narrative Around Arvinas Is Shifting Amid Strategic Moves and Analyst Uncertainty
Arvinas stock has seen its fair value estimate hold steady at $12.31 per share, even as the discount rate decreased slightly to 6.96%. This stability comes as analysts weigh varying perspectives on the company's evolving strategy and its implications for future growth. Stay tuned to discover how you can track further updates on Arvinas' shifting narrative as events unfold. Stay updated as the Fair Value for Arvinas shifts by adding it to your watchlist or portfolio. Alternatively, explore our... Dec 2, 2025 - $ARVN
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
NEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Andrew Saik, Chief Financial Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4 at 11:00 a.m. ET in New York. A live audio webcast of the presentation will be a Nov 26, 2025 - $ARVN
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)
NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepdegestrant (ARV-471) have been accepted for presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), taking place December 9–12, 2025 in San Antonio, Texas. Vepdegestrant is a novel investigational PROTAC estrogen receptor (ER) degrader which is b Nov 24, 2025 - $ARVN
Revisiting the Narrative for Arvinas as Analyst Views Shift with New Pipeline and Partner Risks
Arvinas has recently seen its consensus analyst price target drop sharply from $17.44 to $12.31 per share, signaling a more cautious appraisal of its valuation. The discount rate has edged higher from 6.78% to 6.96%, reflecting increased perceived risk. The projected revenue decline has moderated from -25.19% to -20.13%. As analyst sentiment shifts in response to new developments, readers should stay tuned to see how the evolving narrative could influence future stock outlooks and... Nov 18, 2025 - $ARVN
Arvinas (ARVN): Losses Accelerate 7.7% Annually, but Stock Trades at Peer-Low 1.9x Sales
Arvinas (ARVN) remains in the red, with losses increasing at a rate of 7.7% per year over the past five years and revenue projected to grow just 1.1% annually, which is well below the US market average of 10.5%. The company is not expected to turn a profit in the next three years. However, its Price-To-Sales Ratio of 1.9x stands out as attractive compared to both peers, who average 6.7x, and the broader US Pharmaceuticals sector at 4.2x. For investors, this sets up a dynamic where weak growth... Nov 6, 2025 - $ARVN
Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates
Arvinas (ARVN) delivered earnings and revenue surprises of +36.00% and +55.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 5, 2025 - $ARVN
Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update
– Presented positive data from Phase 1 clinical trials with ARV-102 in healthy volunteers and patients with Parkinson’s disease – – Presented preclinical data from ARV-806 demonstrating robust and differentiated activity in models of KRAS G12D-mutated cancer – – Presented preclinical data from ARV-027 demonstrating robust degradation of polyQ-AR in muscle, supporting further evaluation as a potentially disease-modifying therapy in SBMA – – Announced agreement with Pfizer to jointly select a thir Nov 5, 2025 - $ARVN
Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates
Verastem (VSTM) delivered earnings and revenue surprises of -164.71% and +82.80%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 4, 2025 - $ARVN
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple